Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Pulikottil-Jacob

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Infectious Diseases and Therapy|April 19, 2025
An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service SettingMondher Toumi, Ruth Pulikottil-Jacob, Karina Watts, et al.
Patient Preference and Adherence|April 6, 2023
Impact of Potential Symptoms and Risks Associated with Acid Sphingomyelinase Deficiency on Patients and Caregivers: A Best-Worst Scaling StudyCarol Mansfield, Lubomyra Nalysnyk, Dhaivat Joshi, et al.
Journal of Medical Economics|April 3, 2023
Re: The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United StatesCamille Rochmann, Marie Fournier, Judy Hull, et al.
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Pharmacoeconomics|October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United KingdomLindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Advances in Therapy|April 19, 2017
Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-AnalysisAndriy Danyliv, Julie Glanville, Rachael McCool, et al.
Advances in Therapy|February 12, 2017
The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-AnalysisAndriy Danyliv, Julie Glanville, Rachael McCool, et al.
Trials|June 3, 2014
Six weeks of home enteral nutrition versus standard care after esophagectomy or total gastrectomy for cancer: study protocol for a randomized controlled trialDavid J Bowrey, Melanie Baker, Vanessa Halliday, et al.
Molecular Genetics and Metabolism Reports|March 12, 2024
Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): Exploring the potential indicators of diagnosis using quantitative and qualitative dataAndrew Doerr, Maliha Farooq, Chad Faulkner, et al.
Advances in Therapy|July 27, 2016
The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UKWrik Ghosh, Rose Wickstead, Lindsay Claxton, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Infectious Diseases and Therapy|April 19, 2025
An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service SettingMondher Toumi, Ruth Pulikottil-Jacob, Karina Watts, et al.
Patient Preference and Adherence|April 6, 2023
Impact of Potential Symptoms and Risks Associated with Acid Sphingomyelinase Deficiency on Patients and Caregivers: A Best-Worst Scaling StudyCarol Mansfield, Lubomyra Nalysnyk, Dhaivat Joshi, et al.
Journal of Medical Economics|April 3, 2023
Re: The budget impact of enzyme replacement therapy in type 1 gaucher disease in the United StatesCamille Rochmann, Marie Fournier, Judy Hull, et al.
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Pharmacoeconomics|October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United KingdomLindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Advances in Therapy|April 19, 2017
Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-AnalysisAndriy Danyliv, Julie Glanville, Rachael McCool, et al.
Advances in Therapy|February 12, 2017
The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-AnalysisAndriy Danyliv, Julie Glanville, Rachael McCool, et al.
Trials|June 3, 2014
Six weeks of home enteral nutrition versus standard care after esophagectomy or total gastrectomy for cancer: study protocol for a randomized controlled trialDavid J Bowrey, Melanie Baker, Vanessa Halliday, et al.
Molecular Genetics and Metabolism Reports|March 12, 2024
Diagnostic odyssey for patients with acid sphingomyelinase deficiency (ASMD): Exploring the potential indicators of diagnosis using quantitative and qualitative dataAndrew Doerr, Maliha Farooq, Chad Faulkner, et al.
Advances in Therapy|July 27, 2016
The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UKWrik Ghosh, Rose Wickstead, Lindsay Claxton, et al.
Pageof 4